IL2 and non-small cell lung carcinoma: In primates, administration of pAg synthetic analogs and low doses of IL-2 expand Vγ9Vδ2 T cells in lung tissue, which in turn confer activity against human non-small cell lung cancer (NSCLC) cell lines by increasing the secretion of IFN-γ, TNF-α, and TRAIL (63).